MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

The Hippo Pathway as a Driver of Select Human Cancers

We discuss cancer-related functions of the Hippo pathway and potential explanations for the cancer-restricted mutation profile of core Hippo pathway genes. Greater understanding of Hippo pathway deregulation in cancers will be essential to guide the imminent use of Hippo-targeted therapies.
Comments Off on The Hippo Pathway as a Driver of Select Human Cancers

ERS/ESTS/EACTS/ESTRO Guidelines for the Management of Malignant Pleural Mesothelioma

New promising targeted therapies, immunotherapies and strategies have been reviewed. Because of limited data on the best combination treatment, we emphasize that patients who are considered candidates for a multimodal approach, including radical surgery, should be treated as part of clinical trials in MPM-dedicated centres.
Comments Off on ERS/ESTS/EACTS/ESTRO Guidelines for the Management of Malignant Pleural Mesothelioma

Metformin-loaded Chitosomes for Treatment of Malignant Pleural Mesothelioma – A Rare Thoracic Cancer

Results demonstrated that Met encapsulated chitosomes possessed enhanced cellular internalization and improved cytotoxic potential. Our findings also supported inhibitory activity of chitosomes against metastatic property of pleural mesothelioma cells. The in-vitro tumor simulation studies further established anti-tumor activity of Met encapsulated chitosomes as supported by reduction in tumor volume and presence of minimal viable cells in tumor mass. The obtained results establish the effectiveness of chitosomes as delivery carrier for Met as treatment alternative for malignant pleural mesothelioma.
Comments Off on Metformin-loaded Chitosomes for Treatment of Malignant Pleural Mesothelioma – A Rare Thoracic Cancer

Acidosis-Induced TGF-β2 Production Promotes Lipid Droplet Formation in Dendritic Cells and Alters Their Potential to Support Anti-Mesothelioma T Cell Response

Interestingly, inhibition of TGF-β2 signaling and diacylglycerol O-acyltransferase (DGAT), the last enzyme involved in triglyceride synthesis, led to a significant restoration of DC activity and anticancer immune response. In conclusion, our study has identified that acidic mesothelioma milieu drives DC dysfunction and altered T cell response through pharmacologically reversible TGF-β2-dependent mechanisms.
Comments Off on Acidosis-Induced TGF-β2 Production Promotes Lipid Droplet Formation in Dendritic Cells and Alters Their Potential to Support Anti-Mesothelioma T Cell Response

HEG1, BAP1, and MTAP Are Useful in Cytologic Diagnosis of Malignant Mesothelioma With Effusion

Conclusion: HEG1 is a good marker for mesothelial differentiation in effusion cytology. HD of CDKN2A is frequently observed in cell blocks from effusions of MMs, and MTAP IHC may act as a surrogate for HD of CDKN2A. Cell block analysis is recommended for effusions of unknown origins with the following methods: IHC with HEG1 and claudin 4 to validate the mesothelial origin, followed by BAP1 and MTAP IHC to confirm malignancy.
Comments Off on HEG1, BAP1, and MTAP Are Useful in Cytologic Diagnosis of Malignant Mesothelioma With Effusion

Gender Differences in Molecular-Guided Therapy Recommendations for Metastatic Malignant Mesothelioma

Conclusions: Our observations suggest that a molecular-guided treatment approach is feasible for the management of advanced malignant mesothelioma. Our analysis revealed gender specific differences in PDGFRα expression that should be further evaluated in clinical trials.
Comments Off on Gender Differences in Molecular-Guided Therapy Recommendations for Metastatic Malignant Mesothelioma

What is Mesothelioma?

Learn more about this fatal cancer, including the causes, symptoms, and treatments for both pleural and peritoneal tumors of the mesothelium at our parent site MesotheliomaCenter.

Use of Programmed Death Ligand-1 (PD-L1) Staining to Separate Sarcomatoid Malignant Mesotheliomas From Benign Mesothelial Reactions

Conclusions. —: Strong diffuse PD-L1 staining using antibody 22C3 supports a diagnosis of SMM when the differential diagnosis is RMPs, but PD-L1 staining is not useful for separating EMMs from RMPs.
Comments Off on Use of Programmed Death Ligand-1 (PD-L1) Staining to Separate Sarcomatoid Malignant Mesotheliomas From Benign Mesothelial Reactions

Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge

The uniquely poor mutational landscape which characterizes MPM appears to derive from a selective pressure operated by the environment; thus, inflammation and immune response emerge as key players in driving MPM progression and represent promising therapeutic targets. Here we recapitulate current knowledge on MPM with focus on the emerging network between genetic asset and inflammatory microenvironment which characterize the disease as amenable target for novel therapeutic approaches.
Comments Off on Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge

Survivin Expression as an Independent Predictor of Overall Survival in Malignant Peritoneal Mesothelioma

A lower PCI, intraperitoneal chemotherapy, systemic chemotherapy and a lower level of survivin were powerful prognostic markers in patients with MPeM. The proposed nomogram provides individual survival prediction for patients with MPeM.
Comments Off on Survivin Expression as an Independent Predictor of Overall Survival in Malignant Peritoneal Mesothelioma

Localized Biphasic Malignant Mesothelioma Presenting as a Giant Pelvic Wall Mass: A Rare Case Report and Literature Review

Conclusions: The localized biphasic MPeM may show following characteristics: (1) with heterogeneous low-density and obscure margin; (2) with low incidence rate of ascites; (3) with few central hemorrhage and necrosis; (4) with few calcified structures; (5) with mild to moderate heterogeneous delayed enhancement on contrast-enhanced CT. The imaging characteristics can provide further information for the diagnosis of localized biphasic MPeM in the future.
Comments Off on Localized Biphasic Malignant Mesothelioma Presenting as a Giant Pelvic Wall Mass: A Rare Case Report and Literature Review